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Abstract
Aim of the study: Combination of ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin (3DDA±RBV) thera-
py is shown to be effective in HCV genotype 1 (GT1) infected patients. However, sparse data exist in patients who 
failed previous boceprevir or telaprevir based therapies. Real life efficacy and safety of this combination were 
evaluated in HCV GT1b infected patients (mostly cirrhotics) with compensated liver disease who failed previous 
boceprevir or telaprevir based therapies more than a year before.
Material and methods: Data of previous protease inhibitor failure patients, treated with 3DAA+RBV for 
12 weeks (GT1b and/or non-cirrhotics) or 24 weeks (non-GT1b cirrhotics), were retrospectively collected.
Results: Population characteristics: boceprevir/telaprevir-failure: 82/45, GT1b: 117, cirrhotic: 111 (87.4%). 
SVR12/24 was observed in 103/105 patients (98.1%) of those who reached either time point. Four SAEs report-
ed: one death due to myocardial infarction, another due to recurrent hepatocellular carcinoma after achieving 
SVR12, two hospitalizations (elevation of transaminases, pneumonia). Grade ≥ 3 AEs or laboratory abnormalities 
were reported in < 10% of patients; they were transient in all patients. No early discontinuation of drugs due 
to SAE has been reported.
Conclusions: One year after previous failure of boceprevir or telaprevir based therapy, 12 weeks of 3DAA+RBV 
combination in HCV GT1b infected patients is similarly effective and safe as in those with no previous HCV ther-
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Introduction 
The first generation NS3/4A protease inhibitors 
(PIs) boceprevir (BOC) and telaprevir (TEL) were reg-
istered in 2011 for the treatment of HCV GT1 infection 
in triple combinations with pegylated interferon plus 
ribavirin (PegIFN+RBV) [1, 2]. A  common reason of 
failure of these PI-based therapies is development of re-
sistance associated substitutions (RASs) [3-5]. To some 
extent, RASs are also present in most HCV infected pa-
tients even without previous antiviral therapy (baseline 
RASs) [4]. Cross-resistance between first generation PIs 
can potentially influence the efficacy of PI-containing 
direct acting antiviral drug (DAA) combinations after 
failure of a previous PI-based regimen. Using a popula-
tion-based sequencing approach, long-term follow-up 
studies have shown the disappearance of RASs in a me-
dian time to loss of mutations in 9 months (TEL) to 
1.04 years (BOC) in the majority of HCV GT1b infected 
patients.
Ombitasvir (HCV NS5A inhibitor), ritonavir (en-
zyme inhibitor) boosted paritaprevir (NS3A/4 prote-
ase inhibitor) and dasabuvir (non-nucleoside NS5B 
polymerase inhibitor) with or without addition of RBV 
(3DAA±RBV) have been registered for the treatment 
of HCV GT1 or GT4 infected patients [6, 7]. However, 
the efficacy of 3DAA±RBV therapy has not been eval-
uated during registration studies in patients who failed 
previous BOC or TEL containing triple therapies. Due 
to financial constraints, use of the 3DAA+RBV com-
bination has been approved in the Hungarian HCV 
guideline for a subgroup of such patients with G1b in-
fection [8].
Real life efficacy and safety of the 3DAA+RBV 
combination in HCV GT1b infected patients with 
compensated liver disease (mainly with cirrhosis), 
who failed previous BOC/TEL-based triple therapy 
more than a  year before, were retrospectively anal-
ysed under the supervision of the Hungarian Hepatitis 
Therapeutics Committee, according to the decision of 
the physicians licensed to treat HCV in Hungary. 
Material and methods 
The decision on therapy was left entirely to the 
treating physicians and to the patients – however, there 
was no alternative reimbursed treatment option avail-
able in Hungary for this patient group. Treatments 
included 3DAA (per label) + RBV (600-1200 mg per 
day according to bodyweight, except patients with ad-
vanced kidney disease with lower doses) for 12 weeks 
(GT1b and all other non-cirrhotics) or 24 weeks (GT1 
non-1b cirrhotics) according to the national guideline 
[8]. Non-GT1b patients were commenced on therapy 
before approval of the Hungarian guideline. Addition 
of RBV to the 3DAA combination in these GT1b in-
fected patients was felt appropriate by consensus of the 
treating physicians in an attempt to maximize efficacy 
and minimize potential relapses.
Therapy-related data were either subtracted from 
the National Hepatitis Treatment Registry (baseline de-
mographics, fibrosis stage by histology and/or transient 
elastography, type and outcome of previous therapy, 
HCV genotype/subtype, baseline/post-treatment HCV 
RNA, baseline ALT) for all consecutively treated pa-
tients or collected voluntarily from the treating physi-
cians (co-morbidity, AE, SAE, haematology parameters 
by WHO class, GGT, treatment modification, discon-
tinuation) in this retrospective cohort. Sustained viro-
logical response (SVR12/24) was defined as confirmed 
undetectable HCV RNS at post-treatment week 12 and/
or week 24 combined. Post-treatment week 12 PCR is 
not mandatory, and not routinely reimbursed in Hun-
gary; however, it was made available for a proportion 
of patients from an unrestricted research grant. Not all 
of the included patients have reached post-treatment 
week 12 or 24 time points by the database lock. Intent to 
treat (ITT) analysis included all patients who initiated 
therapy, modified ITT (mITT) analysis those who com-
pleted the assigned 12 or 24 weeks therapy and were 
available for SVR12 and/or SVR24 assessment.
HCV RNA was assayed by either Abbott Real-Time 
or Roche COBAS AmpliPrep/TaqMan HCV v2.0 stan-
apy, even in the presence of cirrhosis. These findings might be of particular interest in settings where alternative 
therapies for such patients are not available or not affordable.
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dard methods with lower limits of HCV target detec-
tion (LLD) of 12 or 15 IU/ml, respectively. 
For patients with viral failure baseline RASs were 
retrospectively analysed from samples collected prior 
to therapy [9].
Statistical methods
Number and percentage of patients in different cate-
gories are reported, and descriptive statistical methods, 
including means or medians as well as standard error of 
the mean or range values, were used.
As pre-defined, members of the Hungarian Hepati-
tis Therapeutics Committee, and colleagues contribut-
ing with data of at least four patients or with RAS testing 
are listed as authors.
This was a  retrospective, purely observational study 
with retrospective data collection. For this reason it is 
not registered in any clinical trial registries and no ethics 
committee review has been requested. However, the 
procedures followed were in accordance with the Hel-
sinki Declaration of 1975, as revised in 1983.
Results
Patient population
Out of 127 patients enrolled, at the closure of data 
collection, SVR12 and/or SVR24 results were available 
for 104 patients. One patient was lost to follow-up prior 
to the end of treatment (included in the ITT analysis, 
but not included in the mITT analysis), while 22 pa-
tients did not reach the EOT+24 week time point and 
have no available EOT+12 week HCV RNA result either 
(not routinely assessed in Hungary). These 22 patients 
are not included in the ITT/mITT SVR analyses. 
Baseline characteristics of patients are shown in Ta-
ble 1. The majority of patients were cirrhotics (87.4%) 
Table 1. Baseline characteristics of patients
Parameter Boceprevir Telaprevir Total
Number of patients, n 82 45 127
Female/male, n/n 48/34 22/23 70/57
Age, mean ± SEM (range), years 59.4 ± 5.2 (45-74) 57.6 ± 5.8 (34-70) 58.8 ± 5.4 (34-74)
Body weight, mean ± SEM (range), kg 79.8 ± 10.9 (54-116) 81.3 ± 14.1 (54-119) 80.4 ± 12.8 (54-119)
BMI, mean ± SEM (range), kg/m2 28.3 ± 3.6 (20.5-48.9) 28.2 ± 3.8 (20.8-49.5) 28.2 ± 4.0 (20.5-49.5)
Liver stiffness, mean ± SEM (range), kPa 29.7 ±11.0 (6.9-73.5) 27.8 ± 11.9 (8.5-75.0) 28.9 ± 11.1 (6.9-75.0)
Oesophageal varices reported, n 4 1 5
Platelet count < 75.0 × 109/l, n (%) 19 (25.6) 9 (20.0) 28 (22.0)
Fibrosis stage (METAVIR or FibroScan) 
   < F3, n 5 3 8
   F3, n 3 5 8
   F4 (cirrhosis), n (%) 74 (90.2) 37 (82.2) 111 (87.4)
Liver function tests 
   Elevated baseline ALT, n (%) 73 (89.0) 42 (93.3) 115 (90.6)
   Elevated baseline GGT, n/available (%) 44/67 (65.7) 24/39 (61.5) 68/106 (64.2)
HCV subtype 
   GT1b, n (%) 74 (90.2) 43 (95.6) 117 (92.1)
   GT1 non-1b, total, n (%) 8 (9.8) 2 (4.4) 10 (7.9)
   GT1a, n 2 2 4
   GT1a+1b, n 2 0 2
   GT1, subtype untypable, n 4 0 4
HCV baseline viral load 
   HCV RNA, median (range), MIU/ml 0.94 (< 0.1-19.2) 1.27 (< 0.1-12.1) 0.99 (<0.1-19.2)
   HCV RNA viral load ≤ 0.8 MIU/ml, n (%) 37 (45.1) 17 (37.8) 54 (42.5)
   HCV RNA viral load > 0.8 – ≤ 2 MIU/ml, n (%) 22 (26.9) 14 (31.1) 36 (28.4)
   HCV RNA viral load > 2 MIU/ml, n (%) 23 (28.0) 14 (31.1) 37 (29.1)
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and GT1b subtype infected (92.15%). Of note, co-mor-
bidities were reported in 89% of patients.
Efficacy 
Disposition of patients and key HCV RNA results 
are shown in Figure 1, while detailed virological out-
comes for patients who reached the pre-defined time 
points are listed in Table 2. 
By the EOT time point one patient died due to 
myocardial infarction, one did not attend this visit, 
while 125/127 reached undetectable or detectable with 
below the LLD HCV RNA (98.4% in ITT analysis, 
100.0% in mITT analysis). After reaching SVR12, an 
additional patient with non-subtypable GT1 infection 
died due to recurrent HCC and deterioration of liv-
er functions. In ITT or mITT analysis, SVR12 (where 
HCV RNA tests were performed), SVR24 and com-
bined SVR12/24 results were 81/83 (97.6%) or 81/82 
(98.8%), 74/77 (96.1%) or 74/75 (98.7%) and 103/105 
(98.1%) or 103/104 (99.0%), respectively (Table 2). All 
10 non-GT1b patients have reached SVR12/24 results. 
Separate analysis of BOC versus TEL failure patients 
was considered senseless with one single viral failure 
in this cohort. Normalization of ALT was reported in 
94/105 patients (89.5%).
Virological failure was observed only in one patient, 
a  56-year-old male, with GT1b HCV infection and 
compensated liver cirrhosis, with advanced fibrosis on 
transient elastography (liver stiffness 39.7 kPa), treated 
previously with BOC triple therapy with an outcome 
of relapse. This obese patient (BMI 37.2 kg/m2) with 
no other relevant co-morbidities received a  relative-
ly low dose of RBV (600 mg per day) due to grade 4 
anaemia during previous BOC-based treatment. He 
was reportedly adherent to the therapy (HCV RNA was 
undetectable at the EOT time point). NS3A/4 baseline 
RASs were detected in this patient (Table 3). On relapse 
12 weeks after 3DAA therapy, a sample for RAS re-test-
ing was taken. However, due to technical reasons, this 
sample could not be analysed. This patient was subse-
quently treated with sofosbuvir/ledipasvir + ribavirin 
(800 mg per day) therapy for 24 weeks, and reached 
an SVR.
No specific adherence measures have been applied 
in this real-life data collection. However, the EOT re-
sults suggest excellent adherence to the therapy; only 
one patient did not attend the EOT visit (but attended 
later the EOT+24 weeks visit).
Safety
Four (3.1%) SAEs have been reported in this co-
hort. One patient with a past medical history of coro-
nary artery disease died due to myocardial infarction 
during the second week of 3DAA+RBV therapy. No 
Parameter Boceprevir Telaprevir Total
Response to previous therapy 
Non-response, n (%) 47 (57.3) 17 (37.8) 64 (50.4)
Breakthrough, n (%) 0 5 (1.1) 5 (3.9)
Relapse, n (%) 21 (25.6) 12 (26.7) 33 (26.0)
Unknown/early termination, n (%) 14 (17.1) 11 (24.4) 25 (19.7)
Relevant reported co-morbidities 
Other liver diseases, n 3 1 4
HBV co-infection, n 0 0 0
HIV co-infection, n 0 2 2
Hypertension, n (%) 34 (41.5) 20 (44.4) 54 (42.5)
Diabetes mellitus, n (%) 23 (28.0) 7 (15.6) 30 (23.6)
Coronary artery disease, n (%) 9 4 13 (10.2)
Thyroid disease, n (%) 9 4 13 (10.2)
GERD, n (%) 7 4 11 (8.7)
Depression, n 6 3 9 (7.1)
Cryoglobulinemia ± vasculitis, n (%) 6 1 7 (5.5)
End stage kidney disease (PD), n 1 2 (1) 3 (1)
n – number of patients, SEM – standard error of mean, HCV – hepatitis C virus, ALT – alanine aminotransferase, GGT – gamma-glutamyl transpeptidase, GT – genotype,  
RNA – ribonucleic acid, HBV – hepatitis B virus, HIV – human immunodeficiency virus, GERD – gastroesophageal reflux disease, PD – peritoneal dialysis
Table 1. Cont.
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All patients
N = 127
Combined SVR12 or SVR24
n = 103§
HCV RNA not available
n = 1
HCV RNA < 15 IU/ml
n = 1
HCV RNA negative
n = 124
HCV RNA not performed
n = 22
HCV RNA positive
n = 1
HCV RNA negative
SVR12: n = 81
HCV RNA performed
n = 82
HCV RNA positive
n = 1
HCV RNA negative
SVR24: n = 74
Lost to follow up
before EOT timepoint*
n = 1
In follow up after EOT 
timepoint
n = 22
Lost to follow up after 
EOT + 12 weeks timepoint#
n = 1
Reached EOT
timepoint
n = 126
Reached EOT + 12 weeks
timepoint
n = 104
Reached EOT + 24 weeks
timepoint
n = 75
In follow up after
EOT + 12 weeks timepoint
n = 28
HCV RNA < 15 IU/ml
or HCV RNA negative
n = 125
*One patient died due to myocardial infarction while on therapy; not included in modified ITT analysis. 
# One patient reached SVR12, but died due to recurrent hepatocellular carcinoma and deterioration of liver disease before EOT+24 weeks time point; not included in modified ITT SVR24 
analysis. 
§50 patients had negative HCV RNA testing at both EOT+12 and EOT+24 time points; all other patients had HCV RNA testing only at one of these time points.
EOT – end of treatment, HCV – hepatitis C virus, ITT – intent to treat, N – number of patients, RNA – ribonucleic acid, SVR – sustained virological response
Fig. 1. Disposition of patients and key HCV RNA results
Table 2. Virological outcomes for patients who reached the pre-defined time points
Parameter EOT EOT+12 weeks EOT+24 weeks EOT+12 or EOT+24 
weeks combined
Number of patients evaluated at the time point, N 127 83 77 105
In follow-up at the time point, n 0 22 50 22
Lost to follow-up, n 1* 1* 2*# 1*
Missed visit, n 1 22§ 0 0
Patients with available HCV RNA data, n 125 82 75 104
HCV RNA target detected, quantifiable, n  0 1 1 1
HCV RNA target detected, below LLD, n  1 0 0 0
HCV RNA target not detected, n/N (%) 124 81 74 103
Virological response rate, ITT, n/N (%) 125/127 (98.4) 81/83 (97.6) 74/77 (96.1) 103/105 (98.1)
Virological response rate, mITT, n/N (%) 125/125 (100.0) 81/82 (98.8) 74/75 (98.7) 103/104 (99.0)
*One patient died due to myocardial infarction while on therapy; not included in modified ITT analysis. 
#One patient who reached SVR12 died due to recurrent hepatocellular carcinoma and deterioration of liver disease before EOT+24 weeks time point; not included in modified ITT 
SVR24 analysis.
§HCV RNA testing at EOT+12 weeks time point is not mandatory in Hungary.
N – total number of patients, n – number of patients, EOT – end of treatment, HCV – hepatitis C virus, RNA – ribonucleic acid, LLD – lower limit of detection, ITT – intent to treat,  
mITT – modified intent to treat, SVR – sustained virological response
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relevant anaemia was observed during this short peri-
od of therapy. This SAE was considered as not related 
to the 3DAA+RBV therapy by the treating physician. 
After reaching SVR12, one cirrhotic patient with a past 
medical history of cured HCC died due to recurrent 
HCC and deterioration of liver functions. Relation of 
this SAE to the therapy was considered as possible by 
the treating physician. One patient was hospitalized 
due to elevation of liver enzymes (LFTs) > 10× above 
the upper limit of normal. This SAE did not lead to 
therapy discontinuation or modification, and subse-
quently was resolved on continued 3DAA+RBV ther-
apy. A relation to the therapy was considered as likely 
by the treating physician. This patient has reached an 
SVR24. One patient developed pneumonia requiring 
hospitalization. The pneumonia was subsequently re-
solved on antibiotic therapy with no therapy discon-
tinuation or modification. This SAE was considered as 
not related to the 3DAA+RBV therapy by the treating 
physician. The patient has reached an SVR24. 
AEs reported in more than one patient are shown in 
Table 4. Discontinuations, dose reductions, reported rel-
evant on-treatment laboratory abnormalities by WHO 
grade and anaemia management measures are shown in 
Table 5. None of the reported AEs or laboratory abnor-
malities led to therapy discontinuation, and reportedly 
all of them resolved without sequelae during or after the 
therapy. No grade 3 or 4 anaemia has been reported. 
Grade 1 anaemia was reported in 24 patients, but only 
9 required RBV dose reduction (by 200-400 mg).
Discussion 
According to our knowledge, this is the largest data-
set on the efficacy and safety of 3DAA+RBV combina-
tion therapy in HCV infected patients who failed pre-
vious BOC/TEL based triple therapy. The 3DAA+RBV 
combination is not registered for the treatment of 
HCV infected patients who failed previous BOC/TEL 
containing triple therapies, and is not recommended 
for this patient category by international professional 
guidelines [6, 7]. However, with no other therapeutic 
option available in Hungary at the time of initiation of 
Table 3. Resistance associated substitutions (RASs) detected for different non-structural proteins (NS) at baseline in patient with relapse 
Category of RAS NS3A/4 NS5A NS5B (non-nucleotide)
RAS(s) detected A156A/T
V170I
Not tested Not detected
RAS – resistance associated substitution, NS – non-structural protein
Table 4. Adverse events reported in more than one patient
Category Reported 
incidence 
(n = 109)
Projected 
incidence* 
(n = 127)
Weakness, n (%) 8 (7.3) (6.3)
Dry skin or itching, n (%) 6 (5.5) (4.7)
Dry mouth or itching tongue, n (%) 4 (3.7) (3.1)
Cough, n (%) 3 (2.8) (2.4)
Nycturia, n (%) 3 (2.8) (2.4)
Nausea, n (%) 2 (1.8) (1.6)
Skin rash, n (% 2 (1.8) (1.6)
Dizziness, n (%) 2 (1.8) (1.6)
*Projected incidence: assumption of no adverse event in the patient if not reported  
by the treating physician.
Table 5. Discontinuations, dose reductions, reported relevant on-treatment 
laboratory abnormalities by WHO grade, anaemia management
Category Reported 
incidence 
(n = 109)
Projected 
incidence* 
(n = 127)
Therapy discontinuation/dose modification
Discontinuation of any of the drugs, n (%) 1 (0.9)& (0.8)
Ribavirin dose reduction, n (%) 9 (8.3) (7.1)
Laboratory abnormalities
Transaminase elevation by grade > 1 
from baseline, n (%)
1 (0.9) (0.8)
Hyperbilirubinema
Grade 1, n (%) 3 (2.8) (2.4)
Grade > 1, n 0 0
Anemia
Grade 1, n (%) 24 (22.0) (18.9)
Grade 2, n (%) 2 (1.8) (1.6)
Grade > 2, n 0 0
Neutropenia, any grade, n 0 0
Thrombocytopenia, progressed  
on treatment#, n
0 0
Transfusion/erythropoietin use, n 0 0
*Projected incidence: assumption of no discontinuation/dose reduction/laboratory 
abnormality in patient if not reported by the treating physician.
&This patient died due to myocardial infarction in the second week of therapy.
#Baseline grade ≥ 2 thrombocytopenia improved by at least one WHO grade during  
or after therapy in 5/28 patients (17.9%).
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this programme, use of this combination has been ap-
proved in the Hungarian National HCV guideline for 
previous BOC/TEL-failure patients with G1b infection 
by consensus of treating physicians [8].
In an ITT analysis as high as 98.1% (99.0% in mITT 
analysis) combined SVR12 and/or SVR24 has been ob-
served in this dominantly HCV GT1b infected popula-
tion, despite a 87.4% frequency of liver cirrhosis, when 
3DAA+RBV therapy was commenced at least one year 
apart from the previous PI therapy.
Based on our data, this combination seems just as 
effective and safe in patients after PI failure as report-
ed in those with no previous therapy or in those who 
failed previous PegIFN+RBV dual therapy. The effica-
cy outcomes are also in line with those achieved us-
ing any other registered therapies after PI failure, in-
cluding combinations of daclatasvir+sofosbuvir±RBV, 
grazoprevir/elbasvir, ledipasvir/sofosbuvir+RBV or vel-
patasvir/sofosbuvir (95% to 100% in different studies) 
[10-13].
Only one out of 105 patients who reached the 
EOT+12 weeks time point experienced virological fail-
ure (relapse). NS3A/4 RASs could be detected prior to 
3DAA therapy, and a relatively low dose (5.5 mg/kg) of 
ribavirin was taken by this patient. This patient could 
be rescued and reached an SVR subsequently with 
sofosbuvir/ledipasvir + ribavirin therapy, the other 
IFN-free combination available in our country.
Reported SAEs, AEs and laboratory abnormalities 
matched the frequencies of such events in patients 
treated with RBV containing 3DAA regimens in reg-
istration trials [6, 7]. Although the dose of RBV was 
reduced in a proportion of patients (8.3%), no transfu-
sion, no erythropoietin use and no therapy discontin-
uation have been reported due to anaemia.
Similarly positive real life experiences have been 
demonstrated in PI-failure HCV GT1 infected patients 
when treated with 3DAA±RBV therapy, with SVR 
rates of 46/48 (96%) and 16/16 (100%) in the German 
hepatitis C registry and in the Polish AMBER cohort 
[14, 15]. 
Strengths and limitations
Viral load, HCV genotype and fibrosis stage data as 
well as previous and current treatment allocations and 
assignments data are reliably registered in the Hun-
garian Hepatitis Registry system (mandatory for treat-
ments). However, all other data were retrospectively 
reported by the treating physicians, and occasionally 
they might not be complete and/or adequate. In par-
ticular, data on co-morbidities, SAEs, AEs, laboratory 
abnormalities and/or RBV dose modifications might 
not be completely reliable. Furthermore, this is an in-
terim analysis with SVR12 or SVR24 data available 
only for a proportion of patients who started therapy. 
In addition, there is no control/parallel group in this 
retrospective cohort for a direct comparison to either 
different patient populations or different therapy reg-
imens. With no comparative RBV-free arm in the co-
hort, the hypothesized benefit of adding RBV to the 
3DAA combination in this PI-failure patient popula-
tion (with several additional negative factors: 87.4% 
cirrhotics, co-morbidities in 89% of patients) remains 
unclear. 
In conclusion, when administered at least one year 
apart, the 3DAA+RBV combination was found effec-
tive and safe in HCV GT1 infected patients who failed 
previous BOC/TEL-based therapies in this cohort, 
regardless of presence or absence of liver cirrhosis. 
Although these findings might not be of pivotal im-
portance in many countries with unlimited access to 
effective IFN-free combinations, they might still be of 
particular interest in settings where other therapies for 
such patients are not available or not affordable.
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County Kaposi Mór Teaching Hospital, Kaposvár, n = 1), 
Horváth G (Főváros Önkormányzat Szent János and 
Észak-budai Egyesített Hospitals and Hepatology Centre 
of Buda, Budapest, n = 9), Hunyady B (Somogy County 
Kaposi Mór Teaching Hospital, Kaposvár and Universi-
ty of Pécs, Pécs, n = 2), Jancsik V (Kenézy Gyula Hospi-
tal and Outpatient Clinic, Debrecen, n = 9), Lengyel G 
(Semmelweis University, Budapest, n = 4), Lombay B 
(Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi 
Oktató Kórház, Miskolc, n =1), Makara M (Fővárosi 
Önkormányzat Egyesített Szent István and Szent Lász-
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ló Hospital, Budapest, n = 7), Makkai E (Magyar Imre 
Hospital, Ajka, n = 6), Martyin T (Békés County Pándy 
Kálmán Hospital, Gyula, n = 2), Müller Zs (Fejér Coun-
ty Szent György University Teaching Hospital, Székesfe-
hérvár, n = 3), Nemesesánszky E (Fővárosi Önkormányzat 
Szent János Kórház és Rendelőintézet, Budapest, n = 1), 
Palatka K (University of Debrecen, Debrecen, n = 2), 
Pár A (University of Pécs, Pécs, n = 2), Pár G (University 
of Pécs, Pécs, n = 1), Pusztay M (Fővárosi Önkormányzat 
Szent János Kórház és Rendelőintézet, Budapest, n = 3), 
Reé J (Fővárosi Önkormányzat Egyesített Szent István 
and Szent László Hospital, Budapest, n = 2), Ribiczey P 
(Zala Coutny Hospital, Zalaegerszeg, n = 6), Schneider F 
(Markusovszky University Teaching Hospital, Szom-
bathely, n = 5), Szalay F (Semmelweis University, Bu-
dapest, n = 1), Szinku Zs (Somogy County Kaposi Mór 
Teaching Hospital, Kaposvár, n = 3), Szlávik J (Fővárosi 
Önkormányzat Egyesített Szent István and Szent László 
Hospital, Budapest, n =2), Tolvaj Gy (Magyar Honvédség 
Medical Centre, Budapest, n = 2), Tornai I (University of 
Debrecen, Debrecen, n = 7), Tusnádi A (Jász-Nagykun-
Szolnok County Hetényi Géza Hospital, Szolnok, n = 5), 
Weisz Gy (Kenézy Gyula Hospital and Outpatient Clin-
ic, Debrecen, n = 1), Werling K (Semmelweis University, 
Budapest, n = 4).
Previous publication
Preliminary data in this cohort have been presented 
in a poster at the International Liver Congress, 2016: 
Hunyady B, Abonyi M, Gervain J, et al. Ombitasvir/
paritaprevir/ritonavir + dasabuvir + ribavirin (3DAA 
+ RBV) treatment of hepatitis C (HCV) genotype 1 
(GT1) infected patients after failure to previous first 
generation protease inhibitor (PI) therapy. Interim 
analysis. ILC 2016. Abstract SAT-120. J Hepatol 2016; 
64 (Suppl 2): S750.
Disclosure
Authors report no conflict of interest.
References
1. European Medicines Agency (EMA). Victrelis. Summary of prod-
uct characteristics. Updated: 23/06/2016. Available from: http://
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Product_Information/human/002332/WC500109786.pdf
2. European Medicines Agency (EMA). Incivo. Summary of product 
characteristics. Updated: 06/10/2016. Available from: http://www.
ema.europa.eu/docs/en_GB/document_library/EPAR_-_Prod-
uct_Information/human/002313/WC500115529.pdf
3. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treat-
ment-emergent resistant variants in telaprevir phase 3 clinical 
trials. Clin Infect Dis 2013; 57: 221-229. 
4. Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants 
with decreased sensitivity to direct-acting antivirals (DAAs) were 
rarely observed in DAA-naive patients prior to treatment. J Virol 
2013; 87: 1544-1553. 
5. Howe AY, Long J, Nickle D, et al. Long-term follow-up of patients 
receiving boceprevir for treatment of chronic hepatitis C. Antiviral 
Res 2015; 113: 71-78. 
6. European Medicines Agency (EMA). Viekirax. Summary of prod-
uct characteristics. Updated: 25/08/2016. Available from: http://
www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/hu-
man/medicines/003839/human_med_001838.jsp&mid=WC-
0b01ac058001d124
7. European Medicines Agency (EMA). Exviera. Summary of prod-
uct characteristics. Updated: 24/05/2016. Available from: http://
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Product_Information/human/003837/WC500182233.pdf
8. Hunyady B, Gerlei Z, Gervain J, et al. Diagnosis, treatment, and 
follow-up of hepatitis C virus related liver disease. Hungarian na-
tional consensus guideline. Orv Hetil 2015; 156 (Suppl 1): 3-23 [In 
Hungarian].
9. Dietz J, Susser S, Vermehren J, et al. Patterns of resistance-associ-
ated substitutions in patients with chronic HCV infection follow-
ing treatment with direct-acting antivirals. Gastroenterology 2018; 
154: 976-988. 
10. European Medicines Agency (EMA). Daklinza. Summary of prod-
uct characteristics. Updated: 19/10/2016. Available from: http://
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Product_Information/human/003768/WC500172848.pdf 
11. European Medicines Agency (EMA). Harvoni. Summary of prod-
uct characteristics. Updated: 28/07/2016. Available from: http://
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Product_Information/human/003850/WC500177995.pdf
12. European Medicines Agency (EMA). Epclusa. Summary of prod-
uct characteristics. Published: 28/07/2016. Available from: http://
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Product_Information/human/004210/WC500211151.pdf
13. European Medicines Agency (EMA). Zepatier. Summary of prod-
uct characteristics. Published: 28/07/2016. Available from: http://
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Product_Information/human/004126/WC500211235.pdf
14. Hinrichsen H, Wedemeyer H, Christensen S, et al. Real-world 
safety and effectiveness of ombitasvir/paritaprevir/r with dasabu-
vir and/or ribavirin in the German hepatitis C registry. ILC 2016. 
Abstract GS07. J Hepatol 2016; 64 (Suppl 2): S159.
15. Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, et al. Real- 
world effectiveness and safety of ombitasvir/paritaprevir/ritona-
vir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Aliment 
Pharmacol Ther 2016; 44: 946-956.
